Pharmaceutical Companies Shift Focus to Mesothelioma and Other Rare Diseases
News | 22 January 2013
A study released last week reports that pharmaceutical companies are moving away from developing drugs for illnesses affecting the masses, and are concentrating on coming up with new treatments for rare disease sufferers. Nearly one in ten Americans ...
Click on the link to read the full article at MesotheliomaHelp.net (blog)
(This link will open in a new window)
- Bristol-Myers' data on Yervoy and nivolumab causes a stir
- Boehringer Ingelheim transitions to propellant-free Combivent Respimat; names new BMD member
- Encouraging results with Sangamo's SB-728-T in HIV treatment
- Sanofi prepares for regulatory filing of MF candidate on positive JAKARTA study results
- New study shows UCB's Neupro reduces NSBP in RLS patient
